Claims for Patent: 8,795,222

Summary for Patent: 8,795,222

Title:	Device and method for treatment of surface infections with nitric oxide
Abstract:	Topical exposure of nitric oxide gas to wounds such as chronic non-healing wounds may be beneficial in promoting healing of the wound and in preparing the wound bed for further treatment and recovery. Nitric oxide gas may be used, for example, to reduce the microbial infection and burden on these wounds, manage exudate secretion by reducing inflammation, upregulate expression of endogenous collagenase to locally debride the wound, and regulate the formation of collagen. High concentration of nitric oxide ranging from about 160 to 400 ppm may be used without inducing toxicity in the healthy cells around a wound site. Additionally, exposure to the high concentration for a first treatment period reduces the microbial burden and inflammation at the wound site and increase collagenase expression to debride necrotic tissue at the wound site. After a first treatment period with high concentration of nitric oxide, a second treatment period at a lower concentration of nitric oxide preferably ranging from about 5-20 ppm may to provided to restore the balance of nitric oxide and induce collagen expression to aid in the closure of the wound.
Inventor(s):	Stenzler; Alex (Long Beach, CA), Miller; Christopher C. (North Vancouver, CA)
Assignee:	Pulmonox Technologies Corp. (Edmonton, CA) Sensormedics Corporation (Yorba Linda, CA)
Application Number:	13/006,218
Patent Claims:	1. A method for debriding necrotic tissue located at a wound site of a subject, comprising: exposing the wound site to exogenous nitric oxide gas at a concentration and for a period of time sufficient to increase expression of endogenous collagenase at the wound site, wherein the concentration of exogenous nitric oxide gas is from about 120 ppm to about 400 ppm, and wherein the period of time is from about 5 hours to about 72 hours. 2. The method of claim 1, wherein the period of time and concentration of exogenous nitric oxide gas are sufficient to increase expression of endogenous gelatinase at the wound site. 3. The method of claim 1, wherein the period of time and concentration of exogenous nitric oxide gas do not induce significant toxicity to healthy cells surrounding the wound site. 4. The method of claim 1, wherein the concentration of exogenous nitric oxide gas is from about 200 ppm to about 250 ppm. 5. The method of claim 1, additionally comprising mechanically debriding necrotic tissue located at the wound site following exposure to the exogenous nitric oxide gas. 6. The method of claim 1, additionally comprising monitoring the expression of endogenous collagenase at the wound site during exposure to the exogenous nitric oxide gas. 7. A method for debriding necrotic tissue located at a wound site of a subject, comprising: providing a flow-controlled source of gas containing exogenous nitric oxide; and exposing the wound site to exogenous nitric oxide gas from the flow-controlled source of gas at a concentration and for a period of time sufficient to increase expression of endogenous collagenase at the wound site; wherein the increased expression of endogenous collagenase at the wound site contributes to debriding of the necrotic tissue; wherein the concentration of exogenous nitric oxide gas is from about 120 ppm to about 400 ppm; and wherein the period of time is from about 5 hours to about 72 hours. 8. The method of claim 7, wherein the period of time and concentration of exogenous nitric oxide gas are sufficient to increase expression of endogenous gelatinase at the wound site. 9. The method of claim 7, wherein the period of time and concentration of exogenous nitric oxide gas do not induce significant toxicity to healthy cells surrounding the wound site. 10. The method of claim 7, wherein the concentration of exogenous nitric oxide gas is from about 200 ppm to about 250 ppm. 11. The method of claim 7, additionally comprising mechanically debriding necrotic tissue located at the wound site following exposure to the exogenous nitric oxide gas. 12. The method of claim 7, additionally comprising monitoring the expression of endogenous collagenase at the wound site during exposure to the exogenous nitric oxide gas. 13. The method of claim 7, additionally comprising grafting skin onto the wound site. 14. A method of managing exudate from necrotic tissue at a wound site of a subject, comprising: exposing the wound site to exogenous nitric oxide gas at a concentration and for a period of time sufficient to reduce inflammation at the wound site, wherein the concentration of exogenous nitric oxide gas is from about 120 ppm to about 400 ppm, and wherein the period of time is from about 5 hours to about 72 hours. 15. The method of claim 14, additionally comprising providing a flow-controlled source of gas containing exogenous nitric oxide. 16. The method of claim 14, additionally comprising cleaning the wound site prior to exposing the wound site to the exogenous nitric oxide gas. 17. The method of claim 14, additionally comprising applying a gas permeable dressing to the wound site prior to exposing the wound site to the exogenous nitric oxide gas. 18. The method of claim 14, wherein the period of time and concentration of exogenous nitric oxide gas do not induce significant toxicity to healthy cells surrounding the wound site. 19. The method of claim 14, wherein the concentration of exogenous nitric oxide gas is from about 200 ppm to about 250 ppm.

Details for Patent 8,795,222

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2020-12-26